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Blood-brain barrier (BBB) dysfunction might be an important component of many neurodegenerative
disorders. In this study, we investigated its role in dementia using large clinical cohorts. The cerebro-
spinal ﬂuid (CSF)/plasma albumin ratio (Qalb), an indicator of BBB (and blood-CSF barrier) permeability,
was measured in a total of 1015 individuals. The ratio was increased in patients with Alzheimer’s disease,
dementia with Lewy bodies or Parkinson’s disease dementia, subcortical vascular dementia, and fron-
totemporal dementia compared with controls. However, this measure was not changed during preclinical
or prodromal Alzheimer’s disease and was not associated with amyloid positron emission tomography or
APOE genotype. The Qalb was increased in diabetes mellitus and correlated positively with CSF bio-
markers of angiogenesis and endothelial dysfunction (vascular endothelial growth factor, intracellular
adhesion molecule 1, and vascular cell adhesion molecule 1). In healthy elderly, high body mass index
and waist-hip ratio predicted increased Qalb 20 years later. In summary, BBB permeability is increased in
major dementia disorders but does not relate to amyloid pathology or APOE genotype. Instead, BBB
impairment may be associated with diabetes and brain microvascular damage.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cerebrovascular pathology is common in the spectrum of de-
mentia disorders (Snyder et al., 2015). One of the manifestations of
vascular disease in the brain is blood-brain barrier (BBB) dysfunc-
tion (Zlokovic, 2008). The BBB is a selective diffusion barrier at the
level of the cerebral microvascular endothelium that maintains
homeostasis in the central nervous system (CNS) by regulating ion
balance, facilitating nutritional transport, and preventing inﬂux ofniversity Hospital, SE-20502
5657.
sson).
Inc. This is an open access article upotentially neurotoxic molecules from the circulation (Chow and
Gu, 2015). Thus, BBB failure may have detrimental effects on CNS
function, and animal studies have indicated that BBB breakdown
could lead to secondary neuronal injury and neurodegeneration
(Bell et al., 2010; Winkler et al., 2014).
Accumulating evidence suggests that BBB function is compro-
mised in neurodegenerative disorders. Studies investigating BBB
permeability in clinical patient cohorts mainly use 3 experimental
approaches: measurement of the cerebrospinal ﬂuid (CSF)/blood
albumin ratio, histologic assessment of the blood-derived proteins
in the brain tissue, and brain imaging, for example, magnetic
resonance imaging (MRI) or positron emission tomography (PET).
Such investigations have convincingly shown BBB dysfunction in
vascular dementia (VaD) (Skoog et al., 1998; Taheri et al., 2011;nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
S. Janelidze et al. / Neurobiology of Aging 51 (2017) 104e112 105Wada, 1998; Wallin et al., 1990). A recent meta-analysis reported
elevated CSF/serum albumin ratio is in Alzheimer’s disease (AD);
however the effect size was small (Olsson et al., 2016). Studies
subgrouping AD patients have found that AD cases with evidence of
concomitant cerebrovascular pathology have high CSF/serum al-
bumin ratio as a sign of impaired BBB function (Blennow et al., 1990,
1991). In agreement, imaging techniques have mostly detected
slight BBB impairments in AD patients and only in conjunctionwith
vascular pathology (van de Haar et al., 2015). Although evidence of
microvascular lesions has been reported in other dementias, for
example, dementia with Lewy bodies (DLB), Parkinson’s disease
with dementia (PDD), and frontotemporal dementia (FTD) (De
Reuck et al., 2012, 2013), little data are available with respect to
BBB function in these conditions (Janelidze et al., 2015; Llorens
et al., 2015; Sjogren et al., 2004).
Multiple mechanisms have been suggested to underlie BBB
dysfunction in dementia. Accumulation of amyloid b (Ab) in the
vascular wall may lead to endothelial cell damage and disrupt the
BBB in AD (Burgmans et al., 2013; Erickson and Banks, 2013).
Some studies have indicated that BBB breakdown may be linked
to APOE ε4, a major genetic risk factor for nonfamilial AD (Bell
et al., 2012; Halliday et al., 2013; Nishitsuji et al., 2011). We
recently demonstrated that increased BBB permeability in PD and
PDD is related to an abnormal angiogenic CSF proﬁle (Janelidze
et al., 2015). In dementia and other disorders linked to high
risk of dementia (e.g., diabetes, cardiovascular disease), BBB
impairment has also been attributed to adverse effects of
oxidative stress and chronic inﬂammation on endothelial cell
function (Di Marco et al., 2015; Raz et al., 2015). However, BBB
dysfunction has so far been investigated in experimental models
or in small patient cohorts and needs to be validated in larger
clinical material.
In this study, we measured BBB permeability using the CSF/
plasma albumin ratio (Qalb) in 2 different cohorts of in total 1015
individuals including cognitively healthy controls and patients with
subjective cognitive decline (SCD), mild cognitive impairment
(MCI), and with 5 major dementias types, AD, PDD, DLB, VaD,
and FTD. We assessed if the disruption of BBB was associated
with amyloid pathology and the APOE genotype. We also investi-
gated possible risk factors for BBB dysfunction and analyzed
CSF biomarkers of angiogenesis, endothelial damage, and neuro-
inﬂammation to determine if these factors are related to BBB
breakdown in different dementias.
2. Materials and methods
The study was approved by the Regional Ethics Committee in
Lund, Sweden, and the patients and controls gave their informed
consent for research.
2.1. Study participants
2.1.1. Cohort 1
Seventy-ﬁve patients with AD, 34 patients with DLB/PDD, 28
patients with VaD, 41 patients with FTD, and 65 healthy controls
were recruited at the Memory Clinic of Skåne University Hospital
in Malmö, Sweden. We also included 96 individuals with a
baseline diagnosis of MCI. After an average clinical follow-up
period of 5.7 years (3.0e9.6), 35 of these patients had con-
verted to AD (MCI-AD), whereas 61 of them remained cognitively
stable (sMCI).
All patients with a clinical syndrome of dementia met the
Diagnostic and Statistical Manual of Mental Disorders (Third
Edition Revised) (DSM-IIIR) criteria for dementia (American
Psychiatric Association and Work Group to Revise DSM-III,1987) combined with the NINCDS-ADRDA criteria for AD
(McKhann et al., 1984), the NINDS-AIREN criteria for VaD (Roman
et al., 1993), criteria of probable DLB according to the 2005
consensus criteria (Geser et al., 2005), or the 1998 consensus
criteria for FTD (Neary et al., 1998). Patients with MCI at baseline
had to fulﬁll the criteria advocated by Petersen (2004), including
(1) memory complaint, preferably corroborated by an informant;
(2) objective memory impairment adjusted for age and educa-
tion, as judged by the physician; (3) preservation of general
cognitive functioning, as determined by the clinician’s judgment
based on a structured interview with the patient and a Mini-
Mental State Examination (MMSE) score 24; (4) 0 or minimal
impairment of daily life activities; and (5) not fulﬁlling the DSM-
III-R criteria of dementia (American Psychiatric Association and
Work Group to Revise DSM-III, 1987). The healthy participants
were not allowed to have any cognitive complaints or any sig-
niﬁcant neurological or psychiatric illness, and they needed to
have a well-preserved general cognitive functioning. A careful
clinical interview, together with an assessment of global function
(MMSE), delayed recall (Alzheimer’s Disease Assessment Scale
Cognitive Subscale, item 3), attention (a quick test of cognitive
speed), and visuospatial and executive function (cube-drawing
test and clock test), was done to rule out mild cognitive impair-
ment. All subjects were assessed by medical doctors with
extensive experience in cognitive disorders. The characteristics of
cohort 1 are given in Table 1.
2.1.2. Cohort 2
The study population stemmed from the prospective and lon-
gitudinal Swedish BioFINDER study (further information available
at www.bioﬁnder.se). Cohort 2 included 292 cognitively normal
elderly participants recruited from the population-based Malmö
Diet Cancer Study (Berglund et al., 1993), and 384 patients with
mild cognitive complaints enrolled consecutively at 3 memory
outpatient clinics in Sweden. Cognitively normal elderly were
eligible for inclusion if they (1) were aged60 years old; (2) scored
28e30 points on the MMSE (Folstein et al., 1975) at the screening
visit; (3) had absence of cognitive symptoms as evaluated by a
physician; (4) were ﬂuent in Swedish; and (5) did not fulﬁll the
criteria of MCI or any dementia. The exclusion criteria were (1)
presence of signiﬁcant neurologic or psychiatric disease (e.g.,
stroke, Parkinson’s disease, multiple sclerosis, major depression);
(2) signiﬁcant systemic illness making it difﬁcult to participate; (3)
refusing lumbar puncture (LP); and (4) signiﬁcant alcohol abuse.
Data were collected between 2009 and 2014 in accordance with a
standardized protocol. The patients with mild cognitive complaints
were referred for assessment of their cognitive complaints and
were included between 2010 and 2014. They were thoroughly
assessed by physicians with special interest in dementia disorders.
The inclusion criteriawere (1) cognitive symptoms; (2) not fulﬁlling
the criteria for dementia; (3) MMSE score of 24e30 points; (4) age
60e80 years; and (5) ﬂuent in Swedish. The exclusion criteria were
(1) cognitive impairment that without doubt could be explained by
another condition (other than prodromal dementia); (2) severe
somatic disease; and (3) refusing LP or neuropsychological inves-
tigation. These criteria resulted in a clinically relevant population
where 45% were classiﬁed as SCD, 42% as amnestic MCI, and 13% as
nonamnestic MCI. The classiﬁcation was based on a neuropsycho-
logical battery assessing the cognitive domains of verbal ability,
visuospatial construction, episodic memory, and executive func-
tions and the clinical assessment of a senior neuropsychologist. The
characteristics of cohort 2 are given in Table 2.
In both cohorts, the diagnosis of hypertension, diabetes, hyper-
lipidemia, and ischemic heart disease made by a medical doctor
was available from the medical records.
Table 1
Cohort 1: demographic data, clinical characteristics, and CSF levels of biomarkers
Sample characteristics Control (n ¼ 65) sMCI (n ¼ 61) MCI-AD (n ¼ 35) AD (n ¼ 75) DLB/PDD (n ¼ 34) VaD (n ¼ 28) FTD (n ¼ 41)
Sex F/M 42/23 34/27 23/12 51/24 13/21* 13/15 21/20
Age 75 (6) 69 (7)*** 75 (8) 76 (7) 72 (6) 75 (8) 72 (6)*
MMSE 28.7 (1.7) 28.2 (1.2) 26.4 (1.7)*** 19.5 (3.3) *** 21.4 (5.1)*** 21.5 (4.5)*** 22.8 (6.1)***
APOE 1or 2 ε4 alleles 34% 48% 80%*** 65%*** 55%* 21% 28%a
BMI 25.9 (3.7) 25.1 (3.2) 24.3 (4.2) 23.7 (3.6) 25.6 (3.4) 26.5 (5.8) 25.4 (4.1)
Qalb 6.3 (2.9) 6.3 (2.5) 7.1 (3.3) 7.6 (3.4)** 8.4 (4.6)* 8.7 (3.7)** 8.6 (5.5)**
Diabetes, yes/no 4/61 3/58 1/34 9/66 2/32 7/21 0/32
ICAM-1, ng/mL 2.0 (0.7) 1.9 (0.7) 2.1 (0.7) 2.2 (0.7) 2.0 (0.8) 2.1 (0.7) 2.0 (1.0)
VCAM-1, ng/mL 5.4 (1.4) 4.9 (1.5) 5.4 (1.6) 5.7 (1.6) 5.3 (1.4) 5.5 (1.5) 4.9 (1.6)
VEGF, pg/mL 58.0 (19.1) 65.0 (32.0)* 70.9 (21.8)** 73.2 (27.7)** 67.0 (29.0) 80.8 (33.5)** 74.6 (31.6)**
sVEGFR-1, pg/mL 149.2 (55.0) 111.4 (39.7)*** 128.9 (44.7)* 130.3 (41.1)** 103.3 (37.4)*** 100.3 (30.3)*** 118.0 (38.7)**
VEGF/sVEGFR-1 0.4 (0.2) 0.6 (0.3)*** 0.6 (0.2)*** 0.6 (0.2)*** 0.7 (0.4)*** 0.9 (0.4)*** 0.7 (0.3)***
Ab42, pg/mL 675.2 (289.8) 478.9 (195.0)*** 314.5 (78.9)*** 259.7 (105.0)*** 349.6 (172.7)*** 407.4 (187.0)*** 682.9 (290.5)
Ab40, pg/mL 5241 (1487) 3786 (1360)*** 4219 (1327)*** 3899 (1376)*** 3240 (1200)*** 3218 (1345)*** 4530 (1536)*
Data are shown as mean (standard deviation) unless otherwise speciﬁed. Demographic factors and clinical characteristics were compared using 1-way analysis of variance and
chi-square tests. CSF biomarkers and the Qalb were analyzedwith univariate general linearmodels controlling for age and gender, comparedwith controls *p< 0.05, **p< 0.01,
and ***p < 0.001.
Key: Ab, amyloid b; AD, Alzheimer’s disease; BMI, body mass index; CSF, cerebrospinal ﬂuid; DLB/PDD, dementia with Lewy bodies or Parkinson’s disease with dementia;
F, female; FTD, frontotemporal dementia; ICAM-1, intercellular adhesion molecule 1; M, male; MCI-AD, MCI that progressed to AD; MMSE, Mini-Mental State Examination;
Qalb, CSF/plasma albumin ratio; sMCI, stable mild cognitive impairment; sVEGFR-1, soluble VEGF receptor 1; VaD, vascular dementia; VCAM-1, vascular cell adhesionmolecule
1; VEGF, vascular endothelial growth factor.
a APOE data were only available from 18 FTD patients.
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For all patients and controls, blood plasma and CSF samples
were drawn at some point between 8 AM and 12 AM with the
patients nonfasting. CSF was collected in polypropylene tubes
and mixed gently to avoid gradient effects. All samples were
centrifuged within 30 minutes at þ4 C at 2000 g for 10 minutes
to remove cells and debris. Samples were stored in aliquots
at 80 C pending biochemical analysis. The procedure followed
The Alzheimer’s Association Flow Chart for LP and CSF sample
processing (Blennow et al., 2010). CSF Ab42 and Ab40 were
analyzed by Euroimmun immunoassay (EUROIMMUN AG, Lübeck,
Germany).Table 2
Cohort 2: demographic data, clinical characteristics and CSF levels of biomarkers
Sample characteristics Controls (n ¼ 292) SCD (n ¼ 171) MCI (n ¼ 213)
Gender, F/M 176/116 94/77 94/119***
Age, y 73 (5) 70 (6)*** 71 (6)***
MMSE 29.1 (0.9) 28.4 (1.4)*** 27.0 (1.9)***
APOE 1 or 2
ε4 alleles
29% 38%* 49%***
Qalb 5.9 (2.2) 6.0 (2.4) 6.5 (4.0)
Composite SUVRa 1.3 (0.3) 1.4 (0.4)** 1.7 (0.5)***
BMI 26.5 (4.3) 25.1 (3.6) 25.4 (4.2)
Homocysteine,
mmol/L
13.5  4.1 12.6  3.9 13.5  4.1
Diabetes, yes/no 26/266 17/152 20/187
Hyperlipidemia,
yes/no
124/168 22/147 19/188
Ab42, pg/mL 561.9 (199.3) 589.6 (254.6) 470.5 (233.0)***
Ab40, pg/mL 4766 (1753) 4925 (1751) 4760 (1873)
Data are shown as mean (standard deviation) unless otherwise speciﬁed.
Demographic factors and clinical characteristics were compared using 1-way anal-
ysis of variance and chi-square tests. Qalb was analyzed with univariate general
linear models controlling for age and gender, compared with controls *p < 0.05,
**p < 0.01, and ***p < 0.001.
Key: Ab, amyloid b; BMI, body mass index; F, female; M, male; MCI, mild cognitive
impairment; MMSE, Mini-Mental State Examination; Qalb, cerebrospinal ﬂuid/
plasma albumin ratio; SCD, subjective cognitive decline; SUVR, standardized uptake
value ratio.
a Normalized for the cerebellar cortex; amyloid positron emission tomography
data were available from 342 subjects (129 cognitively normal elderly, 102 SCD
patients, and 111 MCI patients).CSF levels of vascular endothelial growth factor (VEGF), solu-
ble VEGF receptor 1 (sVEGFR-1), intracellular adhesion molecule
1 (ICAM-1), and vascular cell adhesion molecule 1 (VCAM-1)
were measured using Growth Factor I and Vascular Injury II kits
according to the manufacturer’s protocol with some modiﬁca-
tions (Meso Scale Discovery, Gaithersburg, MD, USA). Brieﬂy, 10%
bovine serum albumin was added to the blocking buffer for all
the assays, and in Growth Factor I assays, samples were incubated
overnight at þ4 C. Data were collected and analyzed using
SECTOR Imager 6000 reader and Discovery Workbench Software
(www.mesoscale.com). All samples were measured in duplicates,
and the mean of the duplicated was used in the statistical anal-
ysis. Detection limits were 8.1 pg/mL for VEGF, 213.6 pg/mL
for sVEGFR-1, 5.6 pg/mL for ICAM-1, and 257.5 pg/mL for
VCAM-1. The coefﬁcient of variation was <20% for all assays.
The very few samples with coefﬁcient of variation >20% did not
affect the results and were therefore included in the statistical
analysis.
Albumin levels in plasma and CSF were measured by immuno-
turbidimetry on a Roche Cobas Analyzer (Roche Diagnostics,
Bromma, Sweden). The albumin ratiowas calculated as CSF albumin
(mg/L)/plasma albumin (g/L) and was used as a measure of BBB
function.2.3. [18F]ﬂutemetamol PET in cohort 2
Cerebral Ab deposition was visualized with the PET tracer [18F]
ﬂutemetamol (approved by the Food and Drug Administration and
the European Medical Agency). PET/computed tomography (CT)
scanning of the brain was conducted at 2 sites using the same type
of scanner (Gemini, Philips Healthcare, Best, The Netherlands).
Baseline sum images from 90 to 110 minutes post injection were
analyzed using the software NeuroMarQ (provided by GE
Healthcare, Cleveland, OH, USA). A volume of interest template
was applied for the following 9 bilateral regions: prefrontal, pa-
rietal, lateral temporal, medial temporal, sensorimotor, occipital,
anterior cingulate, posterior cingulate/precuneus, and a global
neocortical composite region (Lundqvist et al., 2013). The stan-
dardized uptake value ratio (SUVR) was deﬁned as the uptake in a
volume of interest normalized for either the cerebellar cortex or
pons uptake. Amyloid PET data were available from 342 subjects
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patients).2.4. CT and MRI
In cohort 1, 312 cases underwent CT (n ¼ 266) and MRI (n ¼ 46)
for assessment of white matter changes (WMCs). Imaging was
performed according to the clinical protocols including acquisition
of ﬂuid-attenuated inversion recovery images on a 1.5-T scanner
(Siemens) for MRI or of noncontrast CT images using multiple CT
scanners. WMCs were visually assessed according to the age-
related WMC rating scale developed by Wahlund et al. (2001) for
rating of bothMRI and CTwith high agreement betweenmodalities.
On CT images, WMC were rated in the left and right frontal and
occipital-parietal lobes; temporal lesions were not included
because this location is very rare for WMCs (Bronge, 2002). WMCs
were graded from 0 to 3 points: 0 ¼ no lesions or lesions <5 mm,
1 ¼ presence of lesion 5 mm, 2 ¼ lesions beginning to aggregate,
and 3 ¼ conﬂuent lesions involving almost the entire region.
In cohort 2, 618 study participants (269 controls, 159 SCD, and
190 MCI) were examined using a single 3-T MR scanner (Trio,
Siemens). Automated segmentation of white matter lesions was
performed using the Lesion Segmentation Tool implemented in
SPM8 (http://www.applied-statistics.de/lst.html); this generated a
total white matter lesion volume (mL) for each individual.2.5. Statistical analyses
SPSS (IBM, Armonk, NY, USA) was used for statistical analysis.
Data for VEGF, sVEGFR-1, ICAM-1, VCAM-1, and albumin were
skewed; therefore, all variables were ln transformed before ana-
lyses. In addition to CSF concentrations of angiogenesis biomarkers,
we also used the VEGF/sVEGFR-1 ratio when investigating associ-
ations with clinical data. The rationale for this is that sVEGFR-1 has
direct antagonistic effect on VEGF by sequestering the ligands from
the membrane receptors (Ambati et al., 2006; Kendall and Thomas,
1993; Qi et al., 2013). Consequently, high VEGF/sVEGFR-1 ratios
provide an index of the bioactive levels of VEGF.
In cohort 1, the confounding effects of age, gender, and body
mass index (BMI) were tested with Pearson’s correlation analysis
and Student’s t-tests. None of the measured analytes were associ-
ated with BMI. However, for most analytes, we found correlations
with age and gender differences. Therefore, all subsequent statis-
tical analyses were controlled for age and gender.Fig. 1. The cerebrospinal ﬂuid/plasma albumin ratio (Qalb) in different diagnostic groups an
with stable mild cognitive impairment (sMCI), MCI that progressed to Alzheimer’s disea
(DLB/PDD), vascular dementia (VaD), and frontotemporal dementia (FTD). (B) The Qalb in
noncarriers). Data are presented as mean 95% conﬁdence interval; p-values are from univ
compared with controls.For group-wise comparisons, we used univariate general linear
models. Linear regressions were used to investigate associations
between 2 continuous variables. The study participants were
categorized into groups with normal and pathologic PET status
using the SUVR cutoff >1.42 when normalized for the cerebellar
cortex uptake (Palmqvist et al., 2014). The SUVR cutoff >0.51 with
pons as a reference region was derived using mixture modeling
(Benaglia et al., 2009). We also categorized the study participants
into groups with normal and pathologic CSF signature using the CSF
Ab42/Ab40 ratio cutoff 0.1 (Janelidze et al., 2016). Associations
between the Qalb, [18F]ﬂutemetamol SUVR, and vascular risk fac-
tors were tested in the total sample with univariate and linear
regression models controlling for age, gender, and diagnosis. Alpha
level of signiﬁcance was set at p < 0.05.
3. Results
Demographic and clinical characteristics of cohorts 1 and 2 and
raw untransformed concentrations of CSF analytes are shown in
Tables 1 and 2.
3.1. The Qalb in dementias
3.1.1. Cohort 1 (dementia)
We found that the Qalb differed signiﬁcantly between the
diagnostic groups. Speciﬁcally, the ratio was higher in AD (p ¼
0.007), DLB/PDD (p ¼ 0.037), VaD (p ¼ 0.004), and FTD (p ¼ 0.004)
patients compared with controls (Fig. 1A and Table 1). However,
there were no differences between patients with stable MCI (p ¼
0.690) or in patients with MCI who subsequently progressed to AD
(p ¼ 0.186) compared with controls. These results were similar in
regression models additionally adjusting for the confounding
effects of WML.
3.2. The Qalb and Ab pathology
3.2.1. Cohort 2 (bioﬁnder)
Next we sought to determine if the Qalb was altered in pro-
dromal and preclinical stages of AD in a large cohort of cognitively
healthy individuals and patients with SCD or MCI (cohort 2). To this
end, we compared diagnostic subgroups with pathologic CSF
signature (control-P, SCD-P, and MCI-P; CSF Ab42/Ab40 ratio <0.1)
with control subjects showing normal CSF status (control-N; CSF
Ab42/Ab40 ratio0.1). In addition, we investigated if changes in the
Qalb were associated with cortical amyloid deposition measuredd APOE genotypes in cohort 1. (A) The Qalb in cognitively healthy controls and patients
se (MCI-AD), AD, dementia with Lewy bodies or Parkinson’s disease with dementia
different diagnostic groups stratiﬁed according to APOE genotype (APOE ε4 carriers vs.
ariate general linear models controlling for age and gender: *p < 0.05 and **p < 0.01,
Table 3
The Qalb in individuals with normal (CSF Ab42/Ab40 ratio0.1) and pathologic (CSF
Ab42/Ab40 ratio <0.1) CSF signature
Sample characteristics Controls (N),
n ¼ 214
Control (P),
n ¼ 77
SCD (P),
n ¼ 57
MCI (P),
n ¼ 121
Gender F/M 124/90 52/25 26/31 60/61
Age, y 72 (5) 74 (5)** 71 (5) 72 (5)
MMSE 29.2 (0.9) 29.0 (0.9) 28.1 (1.5)*** 26.8 (1.8)***
APOE 1 or 2
ε4 alleles
20% 53%*** 67%*** 68%***
Qalb 6.0 (2.1) 5.8 (2.4) 5.7 (2.2) 6.6 (4.8)
Data are shown as mean (standard deviation) unless otherwise speciﬁed.
Demographic factors and clinical characteristics were compared using 1-way anal-
ysis of variance and chi-square tests. Qalb was analyzed with univariate general
linear models controlling for age and gender, compared with controls **p< 0.01, and
***p < 0.001.
Key: Ab, amyloid b; CSF, cerebrospinal ﬂuid; F, female; M, male; MCI, mild cognitive
impairment; MMSE, Mini-Mental State Examination; N, normal CSF signature; P,
pathologic CSF signature; Qalb, CSF/plasma albumin ratio; SCD, subjective cognitive
decline.
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between any of the diagnostic subgroups (control-N, control-P,
SCD-P, and MCI-P; all p > 0.172, Table 3) and no signiﬁcant corre-
lations between the Qalb and composite [18F]ﬂutemetamol SUVR
(b¼0.111, p¼ 0.052 and b¼0.097, p¼ 0.081 with the cerebellar
cortex or pons as reference regions, respectively). Moreover, there
were no differences in the ratio between study subjects with
normal versus pathologic amyloid PET (p ¼ 0.315 and p ¼ 0.385
with the cerebellar cortex or pons as reference regions,
respectively).3.3. The Qalb and APOE genotype
Previous studies have indicated that APOE might play a role in
maintaining the integrity of the BBB (Zhao et al., 2015). To explore
that association, we compared the Qalb between different APOE
genotypes in cohorts 1 and 2.
3.3.1. Cohort 1 (dementia)
The Qalb did not differ between the APOE ε4 carriers and non-
carriers in any of the diagnostic groups in cohort 1 (all p > 0.081,
Fig. 1B). We did not ﬁnd signiﬁcant differences in the Qalb between
APOE ε4 carriers and noncarriers (p ¼ 0.062) or between carriers of
1 ε4 allele, 2 ε4 alleles, and noncarriers (all p > 0.087) in the total
sample using univariate regression models adjusting for age,
gender, and diagnosis.
3.3.2. Cohort 2 (bioﬁnder)
Conﬁrming our ﬁndings in cohort 1, there were no differences in
the Qalb between APOE ε4 carrier and noncarriers in control (p ¼
0.720), SCD (p ¼ 0.634), or MCI (p ¼ 0.874) groups in cohort
2. Furthermore, there were no differences comparing carriers ofTable 4
Cohort 1: associations between the Qalb and CSF biomarkers of angiogenesis or endothe
CSF biomarkers Control sMCI MCI-AD
ICAM-1 b[ 0.637*** b[ 0.733*** b[ 0.776***
VCAM-1 b[ 0.411** b[ 0.470*** b[ 0.620***
VEGF b[ 0.402** b[ 0.482*** b[ 0.685***
sVEGFR-1 b[ 0.240* b ¼ 0.021 b[ 0.365*
VEGF/sVEGFR-1 b ¼ 0.060 b[ 0.358** b ¼ 0.235
p-Values are derived from linear regression controlling for age and gender; signiﬁcant re
Key: AD, Alzheimer’s disease; CSF, cerebrospinal ﬂuid; DLB/PDD, dementia with Lewy bo
intercellular adhesion molecule 1; MCI-AD, MCI that progressed to AD; Qalb, CSF/plasm
receptor 1; VaD, vascular dementia; VCAM-1, vascular cell adhesion molecule 1; VEGF, v1 ε4 allele, 2 ε4 alleles, and noncarriers (all p > 0.228). The Qalb did
not differ comparing younger (65 years) and older (66 years)
APOE ε4 carrier and noncarriers in SCD and MCI groups
(all p > 0.380).
3.4. The Qalb and CSF biomarkers of angiogenesis or endothelial
damage
Altered Qalb may be related to abnormal angiogenesis and
endothelial cell function (Janelidze et al., 2015; Zlokovic, 2008).
Therefore, we investigated associations between the ratio and CSF
biomarkers of angiogenesis and endothelial dysfunction.
3.4.1. Cohort 1 (dementia)
High Qalb was associated with increased CSF levels of ICAM-1
and VCAM-1 (markers of endothelial dysfunction) in all diag-
nostic groups (Table 4). Moreover, the Qalb positively correlated
with CSF levels of VEGF in control, sMCI, MCI-AD, AD, DLB/PDD, and
FTD groups and with the CSF VEGF/sVEGFR-1 ratio in sMCI, AD,
DLB/PDD, and FTD groups. The associations remained signiﬁcant
after additionally adjusting for WMLs.
Comparing with control subjects, we found that VEGF levels
were increased in sMCI (p ¼ 0.021), MCI-AD (p ¼ 0.008), AD (p ¼
0.002), VaD (p ¼ 0.001), and FTD (p ¼ 0.001) patients, whereas the
VEGF/sVEGFR-1 ratio was increased across all the groups (all p <
0.001, Fig. 2A and B and Table 1). There were no changes in CSF
levels of ICAM-1 or VCAM-1 (Fig. 2C and D and Table 1).
3.5. Risk factors for abnormal Qalb
Finally, we examined associations between the Qalb and po-
tential vascular risk factors in dementia cohorts 1 and 2.
3.5.1. Cohort 1 (dementia)
In cohort 1, the Qalb was increased in individuals with diabetes
(diagnosed with diabetes or taking antidiabetic medications)
compared with those without diabetes (p ¼ 0.015) (Fig. 3A).
Furthermore, diabetes was associated with high CSF levels of ICAM-
1 (p < 0.001), VCAM-1 (p ¼ 0.007), and VEGF (p ¼ 0.024)
(Fig. 3CeE). These results remained signiﬁcant after additionally
adjusting for WMLs. We did not ﬁnd any associations with hyper-
tension (p ¼ 0.633) or ischemic heart disease (p ¼ 0.801).
3.5.2. Cohort 2 (bioﬁnder)
Similar to ﬁndings in cohort 1, the Qalb was increased in in-
dividuals with diabetes in cohort 2 (p ¼ 0.041) (Fig. 3B). Whereas
there was no association with ischemic heart disease (p ¼ 0.281),
plasma homocysteine (p ¼ 0.608), and hyperlipidemia (p ¼ 0.414),
the ratio was higher in patients with hypertension (p ¼ 0.012). In
this cohort, linear regression models revealed no effects of WMLs
on the Qalb (b ¼ 0.018, p ¼ 0.692); therefore, we did not include
WML variable in the statistical analysis. The cognitively healthylial damage
AD DLB/PDD VaD FTD
b[ 0.650*** b[ 0.756*** b[ 0.729*** b[ 0.833***
b[ 0.512*** b[ 0.431* b[ 0.627** b[ 0.679***
b[ 0.458*** b[ 0.719*** b ¼ 0.240 b[ 0.346*
b ¼ 0.092 b ¼ 0.054 b ¼ 0.220 b ¼ 0.075
b[ 0.370** b[ 0.518** b ¼ 0.013 b[ 0.305*
sults are shown in bold; *p < 0.05, **p < 0.01, and ***p < 0.001.
dies or Parkinson’s disease with dementia; FTD, frontotemporal dementia; ICAM-1,
a albumin ratio; sMCI, stable mild cognitive impairment; sVEGFR-1, soluble VEGF
ascular endothelial growth factor; b, standardized coefﬁcient.
Fig. 2. Cerebrospinal ﬂuid (CSF) biomarkers of angiogenesis or endothelial damage in cohort 1. CSF vascular endothelial growth factor (VEGF) (A), the VEGF/soluble VEGF receptor 1
(sVEGFR-1) ratio (B), intercellular adhesion molecule 1 (ICAM-1) (C), and vascular cell adhesion molecule 1 (VCAM-1) (D) were measured in cognitively healthy controls and patients
with stable mild cognitive impairment (sMCI), MCI that progressed to Alzheimer’s disease (MCI-AD), AD, dementia with Lewy bodies or Parkinson’s disease with dementia (DLB/
PDD), vascular dementia (VaD), and frontotemporal dementia (FTD). Data are presented as mean 95% conﬁdence interval; p values are from univariate general linear models
controlling for age and gender: *p < 0.05, **p < 0.01, and ***p < 0.001 compared with controls.
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Study where the ﬁrst assessments of the study participants were
conducted 20.1  1.5 (mean  standard deviation [SD]) years pre-
vious the present study. In this group, linear regression analysis
revealed that high BMI (24.8  3.5, mean  SD) and the waist-hip
ratio (0.8  0.09, mean  SD) in the middle age (53.9  4.7, mean
 SD) predicted increase in the Qalb 20 years later (BMI, b ¼ 0.144,
p ¼ 0.013; waist-hip ratio, b ¼ 0.304, p ¼ 0.003).
4. Discussion
In the present study, we demonstrate that the Qalb is increased
in patients with AD, DLB/PDD VaD, and FTD but not during pre-
clinical or prodromal AD stages. In 2 cohorts comprising a total of
1015 individuals, we did not ﬁnd any associations between the Qalb
and APOE genotype. However, in both cohorts, the ratio was asso-
ciatedwith coexisting diabetesmellitus. Further, the ratio positively
correlated with CSF biomarkers of angiogenesis and endothelial
dysfunction, including VEGF, the VEGF/sVEGFR-1 ratio, ICAM-1, and
VCAM-1. VEGF or the VEGF/sVEGFR-1 ratio was increased in all
dementias and in MCI, whereas patients with diabetes showed
increased CSF levels of VEGF, ICAM-1, and VCAM-1. Last, in the
longitudinal cohort, a high Qalb was related to increased BMI and a
higher waist-hip ratio at the middle age.
Although an elevated Qalb is a consistent ﬁnding in VaD (Skoog
et al., 1998; Taheri et al., 2011; Wada, 1998; Wallin et al., 1990), the
evidence is not clear-cut when it comes to AD (Erickson and Banks,
2013). Nonstringent clinical categorization of AD and VaD (espe-
cially in earlier investigations), bias related to sample size andeffects of age on the ratio have been suggested to account for the
conﬂicting results (Blennow et al., 1990, 1991; Erickson and Banks,
2013). Nevertheless, a recent meta-analysis came out positive with
a small but statistically signiﬁcant 1.1-fold (95% conﬁdence interval
1.01e1.20) increase of Qalb in AD patients compared with control
individuals (Olsson et al., 2016). In the present study, we compared
the Qalb in a relatively large and well-characterized cohort of
cognitively healthy controls and patients with major dementia
disorders using statistical methods adjusting for confounding effect
of age and gender.We found increased Qalb not only in VaD but also
in AD, DLB/PDD, and FTD suggesting that dysfunction of the BBB is
common across different dementia disorders (Janelidze et al., 2015;
Sjogren et al., 2004). Compromised BBB has recently been
demonstrated in the hippocampus of patients with MCI (Montagne
et al., 2015). In contrast, we did not detect any differences in the
Qalb between control and MCI groups. Furthermore, the ratio was
not altered in cognitively healthy individuals who showed a path-
ologic CSF AD biomarker proﬁle and did not correlate with cortical
amyloid deposition. Altogether these results speak against a sig-
niﬁcant causative link between amyloid pathology and BBB
dysfunction at least during the early disease stages. In fact, the BBB
appears intact in the murine models of AD displaying signiﬁcant
amyloid pathology (Bien-Ly et al., 2015).
Some evidence from preclinical models and from human disease
implicated ApoE4 in BBB dysfunction in AD. In transgenic mice,
production of human ApoE4 by astrocytes has been shown to
induce BBB leakage and neurodegeneration (Bell et al., 2012). The
Qalb was found to be higher in cognitively healthy individuals
carrying APOE ε4 than in noncarriers and to increase with age in
Fig. 3. The CSF/plasma albumin ratio (Qalb) and cerebrospinal ﬂuid (CSF) biomarkers of angiogenesis or endothelial damage in diabetes. The Qalb in patients with and without
diabetes in cohort 1 (A) and cohort 2 (B). CSF levels of intercellular adhesion molecule 1 (ICAM-1) (C), vascular cell adhesion molecule 1 (VCAM-1) (D), and vascular endothelial
growth factor (VEGF) (E) in patients with and without diabetes in cohort 1. Data are presented as mean 95% conﬁdence interval; p values are from univariate general linear models
controlling for age, gender, and diagnosis: *p < 0.05, **p < 0.01, and ***p < 0.001.
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Qalb in the considerably larger cohort in the present study showed
no differences between APOE ε4 carriers and noncarriers or be-
tween younger and older APOE ε4 carriers. In agreement with our
ﬁndings, several studies reported no associations between APOE ε4
and BBB breakdown (Bien-Ly et al., 2015; Bowman et al., 2007;
Karch et al., 2013), thus suggesting that APOE genotype is unlikely
to play a role in BBB dysfunction.
Our previous work indicated that in PD high Qalbwas associated
with increased CSF levels of angiogenic factors including VEGF
(Janelidze et al., 2015). In addition to its central role in physiological
and pathologic angiogenesis, VEGF is known to regulate vascular
permeability. In rats, administration of VEGF induces leakage of the
BBB (Zhang et al., 2000). Increased production of VEGF has also
been shown to cause BBB breakdown in experimental models of MS
and cerebral ischemia (Argaw et al., 2012; Suzuki et al., 2015). In the
present study, we found elevated VEGF or the VEGF/sVEGFR-1 ratio
(an index of the bioactive levels of VEGF) in the CSF of patients with
different forms of dementia and positive correlation between VEGF
and the Qalb. Interestingly, CSF levels of VEGF were increased in
MCI and MCI-AD patients who showed no difference in the Qalb
compared with control individuals. These ﬁndings suggest that
abnormal VEGF production may precede BBB breakdown in de-
mentia and provide further support for the link between aberrant
VEGF signaling and BBB dysfunction. We also found an association
between elevated CSF levels of VEGF and coexisting diabetes.
Notably, VEGF pathways have been recently shown to contribute to
impaired BBB and functional recovery in experimental model of
comorbid diabetes and stroke (Reeson et al., 2015).In accordance with the earlier studies (Hawkins et al., 2007;
Starr et al., 2003), we observed associations between disrupted
BBB and diabetes in 2 different cohorts. Obesity is a risk factor for
type-2 diabetes and constitutes an important component of the
metabolic syndrome, and we also show that increased markers for
obesity (BMI and the waist-hip ratio) at the middle age predicts
high Qalb 20 years later. Endothelial and vascular pathology
induced by chronic inﬂammation and oxidative stress are major
complications of diabetes (Tousoulis et al., 2013). Changes in
endothelial cells include upregulation of adhesionmolecules ICAM-
1 and VCAM-1, which are considered biomarkers of peripheral
vascular dysfunction in diabetes (Meigs et al., 2004; Tousoulis et al.,
2013). Here, we demonstrate for the ﬁrst time increased CSF levels
of ICAM-1 and VCAM-1 in diabetic patients and positive correla-
tions between the Qalb and the CSF levels of adhesion molecules
indicating that diabetes may lead to endothelial damage in the
cerebral vasculature. However, the number of individuals with
diabetes was small in the present study; thus, the results require
further validation in larger population.
Another limitation of the present study is that we used Qalb as a
measure for the permeability of the BBB, which is common practice
(Nagga et al., 2014; Reiber, 1994; Tibbling et al., 1977). However,
factors other than disruption of the barrier might affect levels of
albumin in the CSF. In particular, the turnover rate of CSF is slowed
with advancing age and in patients with AD that has been hy-
pothesized to inﬂuence the CSF/serum albumin ratio, with resulting
higher CSF levels of albumin (Erickson and Banks, 2013; Reiber
and Peter, 2001). Although we did adjust for the potentially
confounding effects of age when analyzing our material, we cannot
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the observed high Qalb. Some researchers also caution against
describing Qalb as a BBB marker and state that it actually reﬂects
the blood-CSF barrier at the choroid plexus (Reiber and Peter, 2001).
We cannot exclude the possibility that, for example, vascular
changes in the choroid plexus microvessels may impair function
and thereby lower CSF production rate with a reduced CSF ﬂow rate
that would affect the CSF/serum albumin ratio. On the other hand,
in for example stroke, leaving the choroid plexus intact but injuring
cerebrovascular endothelial cells, the CSF/serum albumin ratio is
increased (Brouns et al., 2011), suggesting that CSF/serum albumin
ratio probably is a marker of both barriers. Altogether, direct as-
sessments of BBB function, such as using dynamic contrast
enhanced MRI and labeled tracers, are warranted to conﬁrm the
results of the present study.
In conclusion, we show that a compromised BBB appears to be a
feature of several different dementias but is not directly associated
with Ab pathology or the APOE ε4 genotype. Our data link BBB
dysfunction with abnormal angiogenic pathways, endothelial
damage, and possibly with diabetes mellitus. These ﬁndings
prompt for future studies investigating molecular mechanisms of
BBB breakdown in dementia disorders and impact of therapeutic
interventions that target these mechanisms.
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